Antibody Response to Mycoplasma pneumoniae: Protection of Host and Influence on Outbreaks? by Roger Dumke & Enno Jacobs
MINI REVIEW
published: 26 January 2016
doi: 10.3389/fmicb.2016.00039
Edited by:
Cécile Bébéar,
University of Bordeaux, France
Reviewed by:
Sabine Pereyre,
University of Bordeaux, France
Katherine Loens,
Antwerp University Hospital, Belgium
*Correspondence:
Roger Dumke
roger.dumke@tu-dresden.de
Specialty section:
This article was submitted to
Infectious Diseases,
a section of the journal
Frontiers in Microbiology
Received: 04 December 2015
Accepted: 11 January 2016
Published: 26 January 2016
Citation:
Dumke R and Jacobs E (2016)
Antibody Response to Mycoplasma
pneumoniae: Protection of Host
and Influence on Outbreaks?
Front. Microbiol. 7:39.
doi: 10.3389/fmicb.2016.00039
Antibody Response to Mycoplasma
pneumoniae: Protection of Host and
Influence on Outbreaks?
Roger Dumke* and Enno Jacobs
Institute of Medical Microbiology and Hygiene, Technische Universitaet Dresden, Dresden, Germany
In humans of all ages, the cell wall-less and genome-reduced species Mycoplasma
pneumoniae can cause infections of the upper and lower respiratory tract. The well-
documented occurrence of major peaks in the incidence of community-acquired
pneumonia cases reported world-wide, the multifaceted clinical manifestations of
infection and the increasing number of resistant strains provide reasons for ongoing
interest in the pathogenesis of mycoplasmal disease. The results of recent studies have
provided insights into the interaction of the limited virulence factors of the bacterium with
its host. In addition, the availability of complete M. pneumoniae genomes from patient
isolates and the development of proteomic methods for investigation of mycoplasmas
have not only allowed characterization of sequence divergences between strains but
have also shown the importance of proteins and protein parts for induction of the
immune reaction after infection. This review focuses on selected aspects of the humoral
host immune response as a factor that might influence the clinical course of infections,
subsequent protection in cases of re-infections and changes of epidemiological pattern
of infections. The characterization of antibodies directed to defined antigens and
approaches to promote their induction in the respiratory mucosa are also preconditions
for the development of a vaccine to protect risk populations from severe disease due to
M. pneumoniae.
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From an evolutionary point of view, Mycoplasma pneumoniae is a successful minimalized
bacterium perfectly adapted to humans as the only known natural host. During the long-term host–
pathogen interaction, the genome of these micro-organisms was reduced to only about 816 kb.
This includes removal of genes coding for cell wall synthesis as well as a reduction of metabolic
capabilities requiring a supply of metabolites from the environment. The adaptation of the
bacterium led to distinct tissue tropism using the surface of the respiratory mucosa as the preferred
niche, which ensures the survival and parasitic life style of these bacteria. The pathogen possesses a
repertoire of factors that cause clinical manifestations after an infection; however, typical virulence
determinants of other pathogenic bacteria, such as type III or IV secretion systems, are lacking
in M. pneumoniae. The species developed an almost unique adherence apparatus. As the main
virulence factor (Atkinson et al., 2008; Atkinson and Waites, 2014), this tip-structured protein
complex determines not only the adhesion process to the respiratory epithelium as a ﬁrst step
in host colonization but also supports a gliding mechanism which results in bacterial motility
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(Miyata, 2010). The close contact of mycoplasmas with
epithelial cells reduces the eﬃciency of mucociliary clearance
processes. Damage to epithelial cells of the mucosa causing
subsequent symptoms is caused by generation of peroxide and
superoxide anion (Hames et al., 2009). In addition, an ADP-
ribosylating and vacuolating community-acquired respiratory
distress syndrome (CARDS) toxin resembling the pertussis toxin
induces ciliastasis and the release of proinﬂammatory cytokines
(Kannan and Baseman, 2006). Further steps in pathogenesis
are mainly determined by local inﬂammation processes and
immunomodulation (Meyer Sauteur et al., 2014).
IMMUNODOMINANT ANTIGENS OF
M. pneumoniae AND HOST RESPONSE
In addition to the role of virulence factors of M. pneumoniae,
the induction of speciﬁc antibodies is not only important
for serodiagnosis of infections but also for the colonization
process. As result of lacking the classical bacterial cell wall,
components of the cell membrane are important for interaction
of the pathogen with the host. The importance of an intact
immune response is demonstrated by the increased occurrence
of severe disease, repeated infections or prolonged persistence
of M. pneumoniae in patients with deﬁciencies of humoral
immunity (Foy et al., 1973; Taylor-Robinson et al., 1980; Roifman
et al., 1986), thus emphasizing the role of speciﬁc antibodies for
protection. The antigens ofM. pneumoniae cells determining the
host response include glycolipids as well as proteins (Morrison-
Plummer et al., 1986) that induce comparable immune reactions
in aﬀected individuals (Jacobs et al., 1986; Vu et al., 1987). In
comparison with glycolipids, the more speciﬁc proteins were
mainly characterized as components of the adhesion apparatus
of M. pneumoniae (Razin and Jacobs, 1992). In particular,
antibodies to the P1 protein are regularly found in sera of
infected patients. The large membrane protein (168 kDa) was
characterized as the main adhesin of the bacteria and is also the
most antigenic protein, inducing strong and early production
of antibodies (Hu et al., 1983). Using diﬀerent proteomic
approaches such as fractionation of whole proteins (Regula et al.,
2001), construction of a whole-genome phage display library
(Beghetto et al., 2009) or 2D separation of proteins followed
by incubation with sera of infected patients (Nuyttens et al.,
2010) resulted in the characterizations of further antigens which
are membrane-associated and potentially interact with the host
immune system. Besides proteins with a conﬁrmed function
in adherence, putative lipoproteins, glycolytic enzymes (e.g.,
pyruvate dehydrogenase subunit B), chaperones (GroEL, DnaK)
and proteins of translation/transcription (e.g., elongation factor
Tu) were found. Some of these proteins are surface-localized
and involved in interactions with components of the human
extracellular matrix (Dallo et al., 2002; Gründel et al., 2015).
In addition, CARDS toxin as an important virulence factor
of M. pneumoniae was characterized as an immune-dominant
protein (Kannan and Baseman, 2006). However, the role of
antibodies to many of these proteins for the potential to protect
the host from re-infections remains to be proved.
With the development of speciﬁc tools for investigation
of mycoplasmas (Halbedel and Stülke, 2007), such as
targeted mutation of TGA triplets coding for tryptophan
in M. pneumoniae (Inamine et al., 1990), the recombinant
production and analysis of proteins of interest for host–pathogen
interaction have accelerated. Regarding naturally infected
hosts, Table 1 summarizes deﬁned M. pneumoniae proteins
that were found in recent years to elicit a speciﬁc and strong
immune reaction in humans. These studies conﬁrmed that
the immune response is dominated by antibodies against the
adhesins and adhesion-related proteins of the bacterium that
have limited eﬀect on viability (Krause and Baseman, 1983). It
can be suggested that the antibody response results mainly in an
inﬂuence on the gliding process (Seto et al., 2005) and a decrease
of adhesion of bacteria to the target cells of the respiratory
mucosa. Studies using quantitative methods to measure the
adherence ofM. pneumoniae to human cells in vitro showed that
speciﬁc antisera to total proteins, to adhesins or even to deﬁned
regions of adhesins are able to inhibit adhesion to more than
90% in comparison with control sera (Svenstrup et al., 2002;
Schurwanz et al., 2009). The importance of the adherence process
for further colonization is underlined by the fact that mutants
defective in expression of diﬀerent adhesins and adhesion-related
proteins are avirulent (Balish and Krause, 2006).
Beside problems in the sensitivity and speciﬁcity of serological
assays (Loens et al., 2010; Busson et al., 2013), M. pneumoniae
infections are complicated by diﬀerent host-dependent
characteristics, such as variable persistence of antibodies,
missing IgM response after re-infection and the infrequent
production of IgA antibodies in children (Atkinson et al., 2008).
IgM antibodies can be detected 7–10 days after infection and IgG
immunoglobulins are measurable approximately 14 days later
(Atkinson et al., 2008; Atkinson and Waites, 2014).
GENOTYPE-SPECIFIC IMMUNE
RESPONSE AND INFLUENCE ON THE
EPIDEMIOLOGY OF M. pneumoniae
INFECTIONS
Genome plasticity and diﬀerent mechanisms for antigen
variation are a typical pattern of diﬀerent mycoplasma species
with pathogenic potential (Citti and Blanchard, 2013). In
M. pneumoniae, recent studies comparing whole genomes
resulted in a remarkable homology between strains of diﬀerent
origin and isolation period (Lluch-Senar et al., 2015; Xiao
et al., 2015). However, isolates of M. pneumoniae or strains
in respiratory tract samples from patients show deﬁned
sequence variations which can be used for typing by diﬀerent
methods. Multilocus variable number of tandem repeat analysis
(Degrange et al., 2009), multilocus sequence typing (Brown
et al., 2015) and SNP minisequencing (Touati et al., 2015) have
been developed recently using current molecular tools. These
approaches investigate variable regions in the genome which
are located mainly in intergenic regions and in genes coding
for hypothetical proteins or for house-keeping proteins with an
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TABLE 1 | RecombinantMycoplasma pneumoniae proteins tested as antigens for detection of specific antibodies in humans.
Protein (gene) Function Remarks Reference
P1 (mpn141∗ ) Adherence Use of C-terminal protein part Drasbek et al., 2004
Full-length characterization using 15 recombinant proteins, construction of a
chimeric protein of C-terminal P1 part and P30
Schurwanz et al., 2009
Construction of a chimeric protein of C-terminal P1 region and parts of P30 and
MPN456 (unknown function)
Montagnani et al., 2010
C-terminal protein part Nuyttens et al., 2010
Conserved C-terminal and variable part of repMP4 of P1-types 1 and 2 Dumke et al., 2012
C-terminal protein part Xue et al., 2013
Immunodominant COOH epitope Wood et al., 2013
Full-length characterization by using four recombinant proteins Chourasia et al., 2014
P30 (mpn453) Adherence Full-length protein Varshney et al., 2008
Fragment of P30 (without N-terminus) Schurwanz et al., 2009
P90 (mpn142) Adherence Fragment of P90 (aa 751–1088) Dumke et al., 2012
P200 (mpn567) Adherence Fragment of P200 (aa 641–678) Dumke et al., 2012
AtpD (mpn598) Energy metabolism Full-length protein Nuyttens et al., 2010
CARDS toxin (mpn372) Cytotoxin Full-length protein Wood et al., 2013
P116 (mpn213) Hypothetical
(adherence?)
Protein fragment (53 kDa) Duffy et al., 1999
Protein fragment (without C-terminus) Drasbek et al., 2004
N-terminal protein region (27 kDa) Tabassum et al., 2010
P400 (mpn400) Hypothetical Fragment of P400 (aa 407–582) Dumke et al., 2012
∗According to Dandekar et al., 2000.
intracellular function. Furthermore, the latter two approaches
detect small polymorphic sites and even single nucleotide
exchanges. Regarding the immune response, an inﬂuence of these
diﬀerences on protective antibodies in infected hosts can hardly
be expected. Also, the role in the immune reaction of more
diﬀerent genome regions such as certain genes that contain copies
of the repetitive element RepMP1 (Musatovova et al., 2012) is still
unclear as the gene products involved and their possible functions
have yet to be investigated. Lipoproteins are important antigens
in many mycoplasma species showing variations to escape the
host immune response (Citti et al., 2010; Szczepanek and Silbart,
2014). In M. pneumoniae, a high proportion (nearly 7%) of
genes encoding for putative lipoproteins was conﬁrmed and their
expression pattern was investigated (Hallamaa et al., 2006, 2008).
So far, strain-speciﬁc induction of anti-lipoprotein antibodies
during infection has not been demonstrated.
The genome region with the greatest discrimination power
in combination with well-characterized gene products is the p1
operon coding for P1 adhesin and the adhesion-related proteins
P40 and P90, as well as a phosphoesterase (mpn140). Copies of
repetitive elements RepMP2/3 and RepMP4 (p1 gene, mpn141)
as well as of RepMP5 (mpn142) can be found, which diﬀer
between isolates (Su et al., 1990). Analysis of repetitive elements
distributed in variable size and sequence over the genome of
M. pneumoniae strains resulted in the characterization of p1 type
1 and p1 type 2 (Spuesens et al., 2009). Despite a high number
of RepMP2/3 (n = 10), RepMP4 (8) and RepMP5 (8) copies in
the genome of strain M129 (Dandekar et al., 2000), the number
of circulating p1 types is relatively low. It can be suggested
that the complex functions of the P1 protein limit the possible
recombination events that allow eﬀective adhesion, gliding
and/or division processes of mycoplasma cells. In addition to
the main types 1 and 2, variants diﬀering to a smaller extent
from the two p1 types (mainly in the RepMP2/3 copy) were
identiﬁed after investigation of sequence of p1 genes of clinical
strains collected world-wide. According to recent knowledge,
these variants cannot be distinguished in the sequence ofmpn142,
indicating lower variability of proteins P40 and P90. Despite
the fact that 76% of the p1 sequence can be assigned to both
RepMP copies, the divergence between the amino acid sequences
of P1 adhesins of types 1 and 2 strains (1,628 and 1,635 aa)
is only about 5%. However, these distinct diﬀerences in amino
acid sequence may inﬂuence the immune response of a colonized
host. Indeed, it was shown that the variable parts of the P1
adhesins are antigenic resulting in a type-speciﬁc response in
immunized animals (Dumke et al., 2008). Thus, recombinantly
produced protein parts derived from variable regions of the
P1 adhesin can be used for determination of type-speciﬁc IgG
immunoglobulins (Dumke et al., 2012). Furthermore, guinea pigs
infected intranasally with a type 2 strain developed protective
immunity to type 2 strains after re-infection with a mixture
of types 1 and 2 (Dumke et al., 2004). As a consequence of
these ﬁndings and because of the dominant role of antibodies
to the P1 protein in sera of infected patients, it has been
suggested that type-speciﬁc immunoglobulins have an inﬂuence
on subsequent re-infections in aﬀected individuals as well as
on the epidemiology of infections in greater populations. The
results of diﬀerent studies conﬁrmed that the epidemic peaks
of respiratory infections due to M. pneumoniae occurring at
intervals of 3–7 years were correlated with a change of the
predominant p1 type (Kenri et al., 2008; Kogoj et al., 2015;
Suzuki et al., 2015; Zhao et al., 2015). In other investigated
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populations, signiﬁcant diﬀerences in the proportion of types 1
and 2 strains during endemic and epidemic periods of infections
were not detected (Dumke et al., 2015; Jacobs et al., 2015).
Therefore, further long-term epidemiological studies are needed
to clarify whether type-speciﬁc antibodies induced after an
outbreak will protect patients from a re-infection with this
genotype ofM. pneumoniae. In a study investigating type-speciﬁc
antibodies in acute-phase sera (IgA and IgG) from pneumonia
patients with known p1 type in the respiratory tract, correlation
between the occurrence of genotypes and type-speciﬁc immune
response was lacking (Dumke et al., 2010). Finally, it cannot be
excluded that genotype-speciﬁc diﬀerences in adhesion-related
proteins will inﬂuence the interaction with target structures for
adherence. Interestingly, recent epidemiological reports describe
the replacement of p1 type 2 strains by variants of this type in
the investigated human population (Jacobs et al., 2015; Suzuki
et al., 2015). The reasons for the shift of genotypes remain unclear
since it seems unlikely that the small sequence variations in the
p1 gene of type 2 and type 2 variant strains will inﬂuence the
immune response of infected patients. Conﬁrmed type-speciﬁc
diﬀerences in factors that inﬂuence the interaction with the host
such as bioﬁlm formation (Simmons et al., 2013) or expression
of CARDS toxin (Techasaensiri et al., 2010; Lluch-Senar et al.,
2015) were demonstrated between types 1 and 2 strains but not
between type 2 and type 2 variants. Further studies should be
performed to give more insight into the role of the time-variable
occurrence of genotype-speciﬁc antibodies (host-dependent) and
the consequences of sequence diﬀerences in the P1 protein for the
adherence process (pathogen-dependent) in the epidemiology of
infections.
VACCINE DEVELOPMENT
Despite the benign course of many infections byM. pneumoniae,
the occurrence of severe manifestations and the existence
of risk populations with intensive person-to-person contacts
(schools, military camps) or with chronic respiratory disease
justify eﬀorts to prevent infections. Recently, a further reason
resulted from high rates of macrolide-resistant strains circulating
mainly in Asia, limiting the antibiotic treatment options
especially in pediatric patients. The availability of safe vaccines
seems nowadays the most eﬀective measure for control of
M. pneumoniae also, and this is supported by the increased
knowledge about the virulence factors and by the conﬁrmed
genetic homogeneity of this pathogen. Furthermore, the
described induction of a strong host immune reaction to deﬁned
pathogen factors has encouraged vaccination experiments.
However, the results of early studies with volunteers treated with
inactivated whole antigen preparations reﬂect the problems of
inducing an immune response that demonstrates eﬀective
protection from subsequent infections (summarized in
Linchevski et al., 2009). Limited eﬃcacy against pneumonia,
adverse reactions and, in some cases, exacerbation of symptoms
after infection of immunized individuals have been described
and conﬁrmed by recent animal experiments (Sekine et al., 2009;
Szczepanek et al., 2012).
Based on the importance of adherence ofM. pneumoniae cells
for initiating host colonization, recent studies have focused on
the induction of adhesion-blocking antibodies. Investigation of
components of the adhesion complex resulted in deﬁned protein
regions which are antigenic and involved in adherence and which
have a conserved sequence (Schurwanz et al., 2009; Nakane
et al., 2011). The construction of chimeric antigens composed
of shorter protein regions with characterized function in
adherence provides an opportunity to target diﬀerent adhesion-
related structures (Schurwanz et al., 2009). Immunization of
guinea pigs with a hybrid protein consisting of adherence-
related parts of the proteins P1 and P30 led to a signiﬁcant
decrease of speciﬁc genome copies in respiratory tract samples
from vaccinated and subsequently infected animals (Hausner
et al., 2013). Since demonstration of the adherence-blocking
properties of sera from immunized animals, the induction of
potent stimulation of mucosal immunity can be suggested as a
crucial aspect for successful vaccination. This included not only
(intranasal) administration of the antigen but also combination
with biocompatible adjuvants (Zhu et al., 2012; Hausner et al.,
2013).
CARRIAGE OF M. pneumoniae
As with other respiratory pathogens such as pneumococci
(Donkor, 2013), asymptomatic or convalescent individuals have
been conﬁrmed as carriers of M. pneumoniae cells in the
upper respiratory tract (Foy, 1993). This is an important fact,
not only for the signiﬁcance of laboratory test results and for
epidemiological aspects of transmission but also for evaluation
of the role of protective antibodies. Unfortunately, the results of
carriage studies are inconsistent. Gnarpe et al. (1992) showed that
culturable mycoplasmas occurred in the throats of a relatively
high proportion (13.5 and 4.6%) of subjectively healthy adults
in two investigation periods. In a recent study, detection of
M. pneumoniae infections using ELISA (IgM and IgG) and
real-time PCR was similar in groups of asymptomatic children
and pediatric patients with respiratory symptoms (Spuesens
et al., 2013). In contrast, Jain et al. (2015) reported a low
rate (<3%) of PCR-positive results in asymptomatic children
in a control group during a period of high incidence of
M. pneumoniae. This is in accordance with other studies that
demonstrated no detection or only low rates of respiratory
tract colonization/infection of asymptomatic patients of diﬀerent
ages (Kumar et al., 2008; Nilsson et al., 2008; Chalker et al.,
2011). Not only the occurrence of asymptomatic carriers but also
the long-term persistence of M. pneumoniae in the respiratory
tract of immunocompetent patients raises doubts regarding the
eﬃciency of the host immune response for clearance of bacteria.
Spuesens et al. (2013) reported that 21% of PCR-positive children
(with or without symptoms) showed carriage of bacteria for 1–
3 months. In a study of 53 patients, the mean carriage time for
M. pneumoniae DNA was 7 weeks after disease onset (up to
7 months) after adequate therapy and conﬁrmation of speciﬁc
antibodies in corresponding sera (Nilsson et al., 2008). Despite
the strong immune response after M. pneumoniae infection, the
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eﬃciency of speciﬁc antibodies to eliminate the bacteria
from the upper respiratory tract seems limited in particular
individuals. The time-dependent decrease of speciﬁc antibodies
in combination with the variable, often low production of IgA
immunoglobulins in the respiratory tract may contribute to re-
infection and long-term carriage.
It should be noted that conﬁrmed persistence and long-term
host colonization are typical for bacteria occurring intracellularly.
The hypothesis is supported by the aforementioned absence of
many metabolic pathways in M. pneumoniae, which requires
close association with the host cells for growth and reproduction.
However, the intracellular localization of M. pneumoniae has
been described in cell culture assays (Meseguer et al., 2003) but
so far not in vivo, so the persistence of mycoplasmas in host cells
as an aspect of pathogenesis remains hypothetical.
CONCLUSION
The infection of immunocompetent patients withM. pneumoniae
induces a strong antibody response which is mainly directed
to surface-located proteins of the adhesion complex of the
mycoplasmas. Thus, an inﬂuence of speciﬁc immunoglobulins
that inhibit the adherence of mycoplasmal cells to the respiratory
epithelium of the host can be expected. However, the occurrence
of long-term carriage of M. pneumoniae, asymptomatic carriers,
re-infections as well as a broad spectrum of extra-pulmonary
manifestations show that the protective eﬀect of speciﬁc serum
antibodies is limited as regards the upper respiratory tract.
The directed movement of bacteria to the base of the ciliated
epithelium of the respiratory mucosa and the specialized
adherence to target cells of the host allow the bacteria to
reach a protected niche. The role of the local immune response
by inhibiting adherence and the immunomodulatory eﬀects
of local inﬂammation on the clinical course have yet to be
explained. These factors are also crucial for the development
of an eﬀective vaccine. Finally, the conﬁrmed induction of
genotype-speciﬁc antibodies raises the question of whether this
has an inﬂuence on re-infections due to diﬀerent genotypes of
M. pneumoniae, which might be important for understanding
the special epidemiology of a common human respiratory tract
pathogen.
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